Inhibitions of complement C3 in patients with autoimmune haemolytic anemia controls haemolysis and increases haemoglobine levels

BestPractice | Jun 2019 | EHA 2019 |

Autoimmune haemolytic anaemia is characterized by haemolysis mediated by autoantibodies directed against red blood cells. Complement C3b deposition on red blood cells plays a central role in autoimmune haemolytic anaemia.  In this MEDtalk Bruno Fattizzo present new data that shows APL-2, a cyclic peptide, has potential as a novel therapeutic for autoimmune haemolytic anaemia.